Erythropoietin protects cardiomyocytes from cell death during hypoxia/reperfusion injury through activation of survival signaling pathways

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Asiya Parvin, A ^a   Raj Pranap, A ^a   Shalini, U ^a   Devendran, Ajay ^a   Baker, John E ^b   Dhanasekaran, Anuradha ^a  

^a ANNA UNIVERSITY   (India)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; ERYTHROPOIETIN; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SURVIVIN; PROTECTIVE AGENT;

ANIMAL CELL; APOPTOSIS; ARTICLE; CALCIUM HOMEOSTASIS; CELL DEATH; CELL HYPOXIA; CELL PROTECTION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HEART MUSCLE CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; RAT; REPERFUSION INJURY; SIGNAL TRANSDUCTION; ANIMAL; CELL LINE; DRUG EFFECTS; METABOLISM;

ANIMALS; CASPASE 3; CELL HYPOXIA; CELL LINE; ERYTHROPOIETIN; MEMBRANE POTENTIAL, MITOCHONDRIAL; PROTECTIVE AGENTS; RATS; REACTIVE OXYGEN SPECIES; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

EID: 84907202527     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107453     Document Type: Article

References (51)

1. Chen Z, Chua CC, Ho Y-S, Hamdy RC, Chua BHL (2001) Overexpression of Bcl-2 attenuates apoptosis and protects against myocardial I/R injury in transgenic mice. American Journal of Physiology-Heart and Circulatory Physiology 280: H2313-H2320.
2. Zong W-X, Thompson CB (2006) Necrotic death as a cell fate. Genes & Development 20: 1-15.
3. Murphy E, Steenbergen C (2008) Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiological reviews 88: 581-609.
4. Lemasters JJ, Theruvath TP, Zhong Z, Nieminen A-L (2009) Mitochondrial calcium and the permeability transition in cell death. Biochimica et Biophysica Acta (BBA) - Bioenergetics 1787: 1395-1401.
5. Rossert J, Eckardt K-U (2005) Erythropoietin receptors: their role beyond erythropoiesis. Nephrology Dialysis Transplantation 20: 1025-1028.
6. Mudalagiri NR, Mocanu MM, Di Salvo C, Kolvekar S, Hayward M, et al. (2008) Erythropoietin protects the human myocardium against hypoxia/reoxygenation injury via phosphatidylinositol-3 kinase and ERK1/2 activation. British journal of pharmacology 153: 50-56.
7. Tramontano AF, Muniyappa R, Black AD, Blendea MC, Cohen I, et al. (2003) Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochemical and biophysical research communications 308: 990-994.
8. Vesey DA, Cheung C, Pat B, Endre Z, Gobe G, et al. (2004) Erythropoietin protects against ischaemic acute renal injury. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 19: 348-355.
9. Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, et al. (2006) Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney international 69: 1806-1813.
10. Koshimura K, Murakami Y, Sohmiya M, Tanaka J, Kato Y (1999) Effects of Erythropoietin on Neuronal Activity. Journal of Neurochemistry 72: 2565-2572.
11. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, et al. (2000) Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97: 10526-10531.
12. Naganska E, Taraszewska A, Matyja E, Grieb P, Rafałowska J (2010) Neuroprotective effect of erythropoietin in amyotrophic lateral sclerosis (ALS) model in vitro. Ultrastructural study. Folia Neuropathol 48: 35-44.
13. Celik M, Gokmen N, Erbayraktar S, Akhisaroglu M, Konakc S, et al. (2002) Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci USA 99: 2258-2263.
14. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, et al. (2003) Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proceedings of the National Academy of Sciences of the United States of America 100: 4802-4806.
15. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, et al. (2003) A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112: 999-1007.
16. Chong ZZ, Kang JQ, Maiese K (2002) Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 106: 2973-2979.
17. Shang YC, Chong ZZ, Wang S, Maiese K (2012) Prevention of β-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL. Aging (Albany NY) 4: 187.
18. Cai Z, Semenza GL (2004) Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury. Circulation 109: 2050-2053.
19. Dhanasekaran A, Gruenloh SK, Buonaccorsi JN, Zhang R, Gross GJ, et al. (2008) Multiple antiapoptotic targets of the PI3K/Akt survival pathway are activated by epoxyeicosatrienoic acids to protect cardiomyocytes from hypoxia/anoxia. American Journal of Physiology - Heart and Circulatory Physiology 294: H724-H735.
20. Lingadurai S, Roy S, Joseph RV, Nath LK (2011) Antileukemic activity of the leaf extract of Bischofia javanica blume on human leukemic cell lines. Indian J Pharmacol 43: 143-149.
21. Chung YM, Lee SB, Kim HJ, Park SH, Kim JJ, et al. (2008) Replicative Senescence Induced by Romo1-derived Reactive Oxygen Species. Journal of Biological Chemistry 283: 33763-33771.
22. Wang G, Gong Y, Burczynski FJ, Hasinoff BB (2008) Cell lysis with dimethyl sulphoxide produces stable homogeneous solutions in the dichlorofluorescein oxidative stress assay. Free Radical Research 42: 435-441.
23. Scaduto Jr RC, Grotyohann LW (1999) Measurement of Mitochondrial Membrane Potential Using Fluorescent Rhodamine Derivatives. Biophysical Journal 76: 469-477.
24. Joshi DC, Bakowska JC (2011) Determination of mitochondrial membrane potential and reactive oxygen species in live rat cortical neurons. Journal of Visualized Experiments: JoVE.
25. Pitrak DL, Tsai HC, Mullane KM, Sutton SH, Stevens P (1996) Accelerated neutrophil apoptosis in the acquired immunodeficiency syndrome. Journal of Clinical Investigation 98: 2714.
26. Braun JS, Novak R, Herzog KH, Bodner SM, Cleveland JL, et al. (1999) Neuroprotection by a caspase inhibitor in acute bacterial meningitis. Nature medicine 5: 298-302.
27. Cho KS, Lee EH, Choi JS, Joo CK (1999) Reactive oxygen species-induced apoptosis and necrosis in bovine corneal endothelial cells. Investigative Ophthalmology & Visual Science 40: 911-919.
28. He Y, Leung KW, Zhang Y-H, Duan S, Zhong X-F, et al. (2008) Mitochondrial Complex I Defect Induces ROS Release and Degeneration in Trabecular Meshwork Cells of POAG Patients: Protection by Antioxidants. Investigative Ophthalmology & Visual Science 49: 1447-1458.
29. Liu Y, Bledsoe G, Hagiwara M, Yang Z-R, Shen B, et al. (2010) Blockade of endogenous tissue kallikrein aggravates renal injury by enhancing oxidative stress and inhibiting matrix degradation. American Journal of Physiology - Renal Physiology 298: F1033-F1040.
30. Le Bras M, Clement MV, Pervaiz S, Brenner C (2005) Reactive oxygen species and the mitochondrial signaling pathway of cell death.
31. O'Malley YQ, Abdalla MY, McCormick ML, Reszka KJ, Denning GM, et al. (2003) Subcellular localization of Pseudomonas pyocyanin cytotoxicity in human lung epithelial cells. American Journal of Physiology-Lung Cellular and Molecular Physiology 284: L420-L430.
32. Festjens N, Vanden Berghe T, Vandenabeele P (2006) Necrosis, a wellorchestrated form of cell demise: Signalling cascades, important mediators and concomitant immune response. Biochimica et Biophysica Acta (BBA) - Bioenergetics 1757: 1371-1387.
33. Higuchi M, Honda T, Proske RJ, Yeh ET (1998) Regulation of reactive oxygen species-induced apoptosis and necrosis by caspase 3-like proteases. Oncogene 17: 2753.
34. Škárka L, OŠ͗ádal B (2002) Mitochondrial Membrane Potential in Cardiac Myocytes. Physiol. Res. pp. 425-434.
35. Gottlieb E, Armour SM, Harris MH, Thompson CB (2003) Mitochondrial membrane potential regulates matrix configuration and cytochrome c release during apoptosis. Cell Death & Differentiation 10: 709-717.
36. Coleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, et al. (2001) Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nature cell biology 3: 339-345.
37. Kroemer G, Zamzami N, Susin SA (1997) Mitochondrial control of apoptosis. Immunology today 18: 44-51.
38. Ly JD, Grubb DR, Lawen A (2003) The mitochondrial membrane potential (Dym) in apoptosis; an update. Apoptosis 8: 115-128.
39. Casciola-Rosen L, Nicholson DW, Chong T, Rowan KR, Thornberry NA, et al. (1996) Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principle of apoptotic death. The Journal of experimental medicine 183: 1957-1964.
40. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, et al. (1995) Yama/CPP32b, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81: 801-809.
41. Patel NS, Sharples EJ, Cuzzocrea S, Chatterjee PK, Britti D, et al. (2004) Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int 66: 983-989.
42. Abdelrahman M, Sharples EJ, McDonald MC, Collin M, Patel NS, et al. (2004) Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 22: 63-69.
43. Cuzzocrea S, Mazzon E, di Paola R, Genovese T, Patel NS, et al. (2005) Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse. Arthritis Rheum 52: 940-950.
44. Taniguchi N, Nakamura T, Sawada T, Matsubara K, Furukawa K, et al. (2010) Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): a pilot, randomized, placebo-controlled study. Circ J 74: 2365-2371.
45. Kao R, Xenocostas A, Rui T, Yu P, Huang W, et al. (2007) Erythropoietin improves skeletal muscle microcirculation and tissue bioenergetics in a mouse sepsis model. Crit Care 11: R58.
46. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, et al. (1998) In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 95: 4635-4640.
47. Sharples EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, et al. (2004) Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 15: 2115-2124.
48. Sepodes B, Maio R, Pinto R, Sharples E, Oliveira P, et al. (2006) Recombinant human erythropoietin protects the liver from hepatic ischemia-reperfusion injury in the rat. Transpl Int 19: 919-926.
49. Sharples EJ, Thiemermann C, Yaqoob MM (2005) Mechanisms of disease: cell death in acute renal failure and emerging evidence for a protective role of erythropoietin. Nat Clin Pract Nephrol 1: 87-97.
50. Brines M, Cerami A (2006) Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int 70: 246-250.
51. Schmeding M, Hunold G, Ariyakhagorn V, Rademacher S, Boas-Knoop S, et al. (2009) Erythropoietin reduces ischemia/reperfusion injury after liver transplantation in rats. Transplant International 22: 738-746.